OBJECTIVE Metformin is the most common treatment for type 2 diabetes (T2D). However,
there have been no pharmacogenomic studies for T2D in which a population of color was …

Aims: To conduct the first GWAS of metformin response, in order to identify genetic
predictors of metformin efficacy in humans and identify potential metformin molecular …

Genome-wide significant loci for metformin response in type 2 diabetes reported elsewhere
have not been replicated in the Diabetes Prevention Program (DPP). To assess …

Objective Genome-wide association studies have uncovered a large number of genetic
variants associated with type 2 diabetes or related phenotypes. In many cases the causal …

Aims/hypothesis Characterisation of genetic variation that influences the response to
glucose-lowering medications is instrumental to precision medicine for treatment of type 2 …

Metformin is one of the most commonly prescribed medications in the world, with 25 million
prescriptions in England in the last year alone (data are from https://openprescribing. net) for …

Purpose Metformin is widely used to treat type 2 diabetes mellitus (T2DM) individuals.
Clinically, inter-individual variability of metformin response is of significant concern and is …

Abstract Objectives Type 2 Diabetes mellitus is a progressive metabolic disease
characterized by relative insulin insufficiency and insulin resistance resulting in …

Despite its widespread use as the first-line agent for the treatment of type 2 diabetes, it has
become clear that metformin does not work optimally for everyone. Elucidating who are the …

Pharmacogenetic studies of antidiabetic drugs have so far focused largely on response to
metformin, which is the first-line therapy for treatment of type 2 diabetes (T2D). The first …